Publications (137)

2023

  1. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  2. Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers

    Cell Death and Differentiation, Vol. 30, Núm. 1, pp. 37-53

  3. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology

2022

  1. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  3. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  4. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

  5. Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium

    Journal of Agricultural and Food Chemistry, Vol. 70, Núm. 41, pp. 13027-13035

  6. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

2021

  1. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance

    Cancers, Vol. 13, Núm. 10

  2. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: A systematic review and individual participant data meta-analysis

    Obstetrical and Gynecological Survey

  3. REPLY:

    Hepatology

  4. REPLY:

    Hepatology

  5. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  6. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs

    Expert Opinion on Investigational Drugs

  7. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

    The Lancet Gastroenterology and Hepatology, Vol. 6, Núm. 7, pp. 547-558

  8. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics

    EBioMedicine, Vol. 73

  9. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

    Hepatology, Vol. 73, Núm. 6, pp. 2311-2325

  10. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

    Aging, Vol. 13, Núm. 19, pp. 23416-23434

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6